The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index; none of the 4 sources its claims cite is checked for support yet.
New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
Open accessAbstract
The Challenge of SARS-CoV-2 Variants The emergence of the SARS-CoV-2 variants B.1.1.7 (VOC-202012/01), 501Y.V2 (B.1.351), and P.1 (B.1.1.28.1) has aroused many concerns, including worsening Covid-1...
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Own result · 4 Own interpretation · 3 Not checked yet · 1 Sources not found · 1 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“was lower by a factor of up to 86, including complete immune escape, for the AZD1222 vaccine (Table 1).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neutralizing activity for the P.1 variant among vaccinated persons was lower by a factor of 6.7 for the BNT162b2 vaccine and by a factor of 4.5 for the mRNA-1273 vaccine (Table 1).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the B.1.1.7 variant showed modest decreases in neutralizing activity in serum samples obtained from vaccinated persons (Table 1).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The serum neutralizing activity for the 501Y.V2 variant among vaccinated persons was lower by a factor of 1.6 to 8.6 for the BBIBP-CorV vaccine, the BNT162b2 vaccine, and the mRNA-1273 vaccine”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the incidence of Covid-19, as confirmed on polymerase chain reaction, was 7.9% among seronegative enrollees and 4.4% among seropositive enrollees in the placebo group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Evidence from the United Kingdom indicates that the B.1.1.7 variant may be associated with a higher risk of death than preexisting variants in the United Kingdom.4”
What the sources say
- Not checked yetcites [4] Horby P, Huntley C, Davies N, et al. NERVTAG paper on COVID-19 variant of concern B.1.1.7. London: Department of Health and Social Care, Scientific Advisory Group for Emergencies, January 2021 (https://www.gov.uk/government/publications/nervtag-paper-on-covid-19-variant-of-concern-b117).
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The 501Y.V2 variant has been estimated to be 50%2 more transmissible than preexisting variants in South Africa”
What the sources say
- Not checked yetcites [2] Pearson CAB, Russell TW, Davies N, et al. Estimates of severity and transmissibility of novel SARS-CoV-2 variant 501Y.V2 in South Africa. London: CMMID Repository, 2021 (https://cmmid.github.io/topics/covid19/sa-novel-variant.html).
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This finding indicates that previous infection with preexisting variants may provide only partial protection from reinfection with the 501Y.V2 variant.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“the 501Y.V2 variant showed complete escape from neutralizing antibodies in 48% of convalescent serum samples (21 of 44) obtained from patients who had previously had Covid-19.5”
What the sources say
- Not matchedcites [5] Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. January 19, 2021 (https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1). preprint. 33654292
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“efficacy in clinical trials was lower for all three vaccines tested in the midst of transmission of the 501Y.V2 variant in South Africa than efficacy in trials conducted in countries with preexisting variants.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: The AZD1222 vaccine's efficacy was 3.2 times higher in the United Kingdom and Brazil than in South Africa (70% vs. 22%).
- Rests on an assumption: The NVX-CoV237 vaccine's efficacy was 1.8 times higher in the United Kingdom than in South Africa (89% vs. 49%).
- Rests on an assumption: The Ad26.COV2.S vaccine's efficacy was 1.3 times higher in the United States than in South Africa (72% vs. 57%).
The paper relies on this without support.
In South Africa, the 501Y.V2 variant increased its share of sequenced viruses from 11% in the first week of October 2020 to 60% in the first week of November 2020 and 87% in the first week of December 2020.
“The 501Y.V2 variant spread rapidly in South Africa, accounting for 11% of the viruses sequenced (44 of 392) in the first week of October 2020, for 60% of those sequenced (302 of 505) in the first week of November 2020, and for 87% of those sequenced (363 of 415) in the first week of December 2020.”
The paper relies on this without support.
In Western Cape, hospital admission rates among diagnosed cases and the clinical characteristics of admitted patients were similar in the first and second waves.
“Hospital admission rates of diagnosed cases and the clinical profile of admitted patients were similar in the first and second waves in Western Cape.”
The paper relies on this without support.
Neutralization activity against the B.1.1.7 variant was modestly reduced by a factor of 1.5.
“the B.1.1.7 variant showed a modest decrease in neutralization activity, by a factor of 1.5”
The paper relies on this without support.
No evidence indicates that antiviral or anti-inflammatory treatments are less effective against the emerging variants than against earlier variants.
“Although there is no evidence that antiviral agents and antiinflammatory treatments are any less effective with the emerging variants than with the preexisting variants”
The paper relies on this without support.
The AZD1222 vaccine's efficacy was 3.2 times higher in the United Kingdom and Brazil than in South Africa (70% vs. 22%).
“Efficacy was higher by a factor of 3.2 with the AZD1222 vaccine in the United Kingdom and Brazil than in South Africa (70% vs. 22%)”
The paper relies on this without support.
The NVX-CoV237 vaccine's efficacy was 1.8 times higher in the United Kingdom than in South Africa (89% vs. 49%).
“higher by a factor of 1.8 with the NVX-CoV237 vaccine in the United Kingdom than in South Africa (89% vs. 49%)”
The paper relies on this without support.
The Ad26.COV2.S vaccine's efficacy was 1.3 times higher in the United States than in South Africa (72% vs. 57%).
“higher by a factor of 1.3 with the Ad26.COV2.S vaccine in the United States than in South Africa (72% vs. 57%)”
The paper relies on this without support.
All three variants carry the N501Y mutation, which replaces asparagine with tyrosine at position 501 in the spike protein's receptor-binding domain.
“All three variants have the N501Y mutation, which changes the amino acid asparagine (N) to tyrosine (Y) at position 501 in the receptor-binding domain of the spike protein.”
The paper relies on this without support.
The 501Y.V2 and P.1 variants each have two further receptor-binding domain mutations, K417N/T and E484K.
“The 501Y.V2 and P.1 variants both have two additional receptor-binding–domain mutations, K417N/T and E484K.”
The paper relies on this without support.
These mutations raise the receptor-binding domain's affinity for the ACE2 receptor.
“These mutations increase the binding affinity of the receptor-binding domain to the angiotensin-converting enzyme 2 (ACE2) receptor.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Reduced protection against any symptomatic COVID-19 disease caused by the B.1.351 variant of concern (now known as the Beta variant) has been reported from clinical trials18, but emerging data suggest that there remains high protection against the important end points of severe disease and hospitalization99.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [18]
In the citing paper
“In light of emerging viral variants with multiple mutations in the S protein — some of which are able to evade both natural and vaccine-induced immunity18 — it is paramount to target both humoral and T cell immunity, and potentially innate immune mechanisms.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [18]
Citations
Cites
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · doi:10.1101/2021.01.18.427166
Self-citation
Cited by
Sorted by citations
Items 101–200 of 561
Muecksch, F., Wise, H. M., Templeton, K. E., Batchelor, B., Squires, M., McCance, K., JARVIS, L. M., Malloy, K., Furrie, E., Richardson, C., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00090-8 · Cited by 48
Experiences and challenges of African traditional medicine: lessons from COVID-19 pandemic
Mutombo, P., Kasilo, O., James, P. B., et al. (2023) · BMJ Global Health · doi:10.1136/bmjgh-2022-010813 · Cited by 43
Papies, J., Emanuel, J., Heinemann, N., Kulić, Ž., Schroeder, S., Tenner, B., Lehner, M. D., Seifert, G., & Müller, M. A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.757666 · Cited by 40
Lee, B., Ko, J., Park, J., Moon, H., Baek, J. Y., Jung, S., Lim, H.-Y., Kim, K.-C., Huh, K., Cho, S. Y., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.822599 · Cited by 41
Zhu, Y., Scholle, F., Kisthardt, S. C., & Xie, D. (2022) · Virology · doi:10.1016/j.virol.2022.04.005 · Cited by 61
“5 large number of variants, of which the emergence of alpha, beta, gamma, and delta variants 78 has shown more pathogenic and transmissible, thus caused potential challenges to use 79 vaccines to completely control the pandemic [26-30].”
COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy
Novelli, G., Biancolella, M., Mehrian‐Shai, R., Colona, V. L., Brito, A. F., Grubaugh, N. D., Vasiliou, V., Luzzatto, L., & Reichardt, J. K. V. (2021) · Human Genomics · doi:10.1186/s40246-021-00326-3 · Cited by 51
Johnson, R., Sharma, J. R., Ramharack, P., Mangwana, N., Kinnear, C. J., Viraragavan, A., Glanzmann, B., Louw, J., Abdelatif, N., Reddy, T., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05110-4 · Cited by 42
Bouton, T. C., Lodi, S., Turcinovic, J., Schaeffer, B., Weber, S. E., Quinn, E., Korn, C., Steiner, J., Schechter-Perkins, E. M., Duffy, E., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab465 · Cited by 49
Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Misra, A., & Theel, E. S. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.00482-21 · Cited by 43
Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2
Kamat, S., Kumari, M., & Jayabaskaran, C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.046 · Cited by 51
Koupaei, M., Naimi, A., Moafi, N., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.740593 · Cited by 40
A fast, ultrasensitive SERS immunoassay to detect SARS-CoV-2 in saliva
Mohammadi, M., Antoine, D., Vitt, M., Dickie, J. M., Jyoti, S. S., Wall, J. G., Johnson, P. A., & Wawrousek, K. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.340290 · Cited by 45
Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Chitsike, L., & Duerksen-Hughes, P. J. (2021) · Virology Journal · doi:10.1186/s12985-021-01624-x · Cited by 45
Yu, X., Wei, D., Xu, W., Liu, C., Guo, W., Li, X., Tan, W., Liu, L., Zhang, X., Qu, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29477-0 · Cited by 38
Neutralization Potential of Covishield Vaccinated Individuals Sera Against B.1.617.1
Yadav, P. D., Sapkal, G. N., Abraham, P., Deshpande, G., Nyayanit, D. A., Patil, D. Y., Gupta, N., Sahay, R. R., Shete, A. M., Kumar, S., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab483 · Cited by 51
Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology
Caldwell, J. M., Le, X., McIntosh, L., Meehan, M. T., Ogunlade, S. T., Ragonnet, R. R., O’Neill, G. K., Trauer, J. M., & McBryde, E. S. (2021) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2021.07.002 · Cited by 36
Goher, S. S., Ali, F., & Amin, M. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2021.100114 · Cited by 47
Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19
Sharma, A., Kontodimas, K., & Bosmann, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.648005 · Cited by 39
COVID-19 and vaccination: myths vs science
Chavda, V. P., Chen, Y., Dave, J. B., Chen, Z., Chauhan, S. C., Yallapu, M. M., Uversky, V. N., Bezbaruah, R., Patel, S., & Apostolopoulos, V. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2114900 · Cited by 37
A Highly Potent SARS-CoV-2 Blocking Lectin Protein
Ahan, R. E., Hanifehnezhad, A., Kehribar, E. Ş., Oğuzoğlu, T. Ç., Földes, K., Özçelik, C. E., Filazi, N., Öztop, S., Palaz, F., Önder, S., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00006 · Cited by 37
Sasaki, M., Toba, S., Itakura, Y., Chambaro, H. M., Kishimoto, M., Tabata, K., Intaruck, K., Uemura, K., Sanaki, T., Sato, A., et al. (2021) · mBio · doi:10.1128/mbio.01415-21 · Cited by 46
Prakash, S., Dhanushkodi, N. R., Zayou, L., Ibraim, I. C., Quadiri, A., Coulon, P.-G. A., Tifrea, D. F., Suzer, B., Shaik, A. M., Chilukuri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328905 · Cited by 42
Christie, M. J., Irving, A. T., Forster, S. C., Marsland, B. J., Hansbro, P. M., Hertzog, P. J., Nold‐Petry, C. A., & Nold, M. F. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd0205 · Cited by 41
Shanmugaraj, B., Khorattanakulchai, N., Panapitakkul, C., Malla, A., Im‐Erbsin, R., Inthawong, M., Sunyakumthorn, P., Hunsawong, T., Klungthong, C., Reed, M. C., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.087 · Cited by 42
Lin, G. S. S., Lee, H. Y., Leong, J. Z., Sulaiman, M. M., Loo, W. F., & Tan, W. W. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267354 · Cited by 34
A Real-World Comparison of SARS-CoV-2 Rapid Antigen Testing versus PCR Testing in Florida
Allan‐Blitz, L., & Klausner, J. D. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01107-21 · Cited by 36
Mechanistic Understanding of Lung Inflammation: Recent Advances and Emerging Techniques
Keskinidou, C., Vassiliou, A. G., Dimopoulou, I., Kotanidou, Α., & Orfanos, S. E. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s282695 · Cited by 50
Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers
Yadav, P. D., Sarkale, P., Razdan, A., Gupta, N., Nyayanit, D. A., Sahay, R. R., Potdar, V. A., Patil, D. Y., Baradkar, S., Kumar, A., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.12.011 · Cited by 30
Tiwari, A., Adhikari, S., Zhang, S., Solomon, T. B., Lipponen, A., Islam, M. A., Thakali, O., Sangkham, S., Shaheen, M. N. F., Jiang, G., et al. (2023) · Water · doi:10.3390/w15061018 · Cited by 61
Budhiraja, S., Indrayan, A., Aggarwal, M., Jha, V., Jain, D., Tarai, B., Das, P., Aggarwal, B. B., Mishra, R., Bali, S., et al. (2021) · medRxiv · doi:10.1101/2021.06.24.21259438 · Cited by 36
SARS-CoV-2 and other viruses in soil: An environmental outlook
Anand, U., Bianco, F., Suresh, S., Tripathi, V. S., Núñez‐Delgado, A., & Race, M. (2021) · Environmental Research · doi:10.1016/j.envres.2021.111297 · Cited by 55
Şahın, D., Tanaçan, A., Anuk, A. T., Sınacı, S., Besımoglu, B., Oluklu, D., Hendem, D. U., Beşer, D. M., Yıldırım, M., Sakcak, B., et al. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06493-5 · Cited by 34
Ramping Up Antimicrobial Peptides Against Severe Acute Respiratory Syndrome Coronavirus-2
Ghosh, S. K., & Weinberg, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.620806 · Cited by 43
Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
Hassan, J., Haigh, C., Ahmed, T., Uddin, M. J., & Das, D. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051066 · Cited by 36
Prieto‐Fernández, E., Egia‐Mendikute, L., Vila-Vecilla, L., Bosch, A., Barreira-Manrique, A., Lee, S. Y., Río, A. G.-D., Antoñana-Vildosola, A., Jiménez-Lasheras, B., Moreno‐Cugnon, L., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1932607 · Cited by 38
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
Cai, Y., Zhang, J., Xiao, T., et al. (2021) · bioRxiv · doi:10.1101/2021.04.13.439709 · Cited by 92
“as documented, to unvaccinated or virus-naïve individuals, may be a less serious concern for those with infection- or vaccine-elicited immunity to the Wu_Hu-1 strain (33).”
BackgroundHow will emerging SARS-CoV-2 variants impact herd immunity?
Lippi, G., & Henry, B. M. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-893 · Cited by 33
da Silva, S. J. R., de Lima, S. C., da Silva, R. C., Kohl, A., & Pena, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.836826 · Cited by 35
Althaus, C. L., Baggio, S., Reichmuth, M. L., Hodcroft, E. B., Riou, J., Neher, R. A., Jacquérioz, F., Spechbach, H., Salamun, J., Vetter, P., et al. (2021) · medRxiv · doi:10.1101/2021.06.10.21258468 · Cited by 32
Wells, C. R., Pandey, A., Fitzpatrick, M. C., Crystal, W., Singer, B. H., Moghadas, S. M., Galvani, A. P., & Townsend, J. P. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100304 · Cited by 38
RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
Liang, Q., Wang, Y., Zhang, S., Sun, J., Sun, W., Li, J., Liu, Y., Li, M., Cheng, L., Jiang, Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104043 · Cited by 31
Modeling the COVID-19 pandemic: a primer and overview of mathematical epidemiology
Saldaña, F., & Velasco‐Hernández, J. X. (2021) · SeMA Journal · doi:10.1007/s40324-021-00260-3 · Cited by 39
A Comprehensive Overview on COVID-19: Future Perspectives
Rana, R., Tripathi, A., Kumar, N., & Ganguly, N. K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.744903 · Cited by 41
Wang, M., Chang, W., Zhang, L., & Zhang, Y. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.77561 · Cited by 35
Devi, P., Maurya, R., Mehta, P., Shamim, U., Yadav, A., Chattopadhyay, P., Kanakan, A., Khare, K., Vasudevan, J. S., Sahni, S., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02311-21 · Cited by 32
SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility
Valério, M., Borges-Araújo, L., Melo, M. N., Lousa, D., & Soares, C. M. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2022.1009451 · Cited by 34
Malcangi, G., Inchingolo, A. D., Inchingolo, A. M., Santacroce, L., Marinelli, G., Mancini, A., Vimercati, L., Maggiore, M. E., D’Oria, M. T., Hazballa, D., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9091964 · Cited by 31
Singer, S. R., Angulo, F. J., Swerdlow, D. L., McLaughlin, J. M., Hazan, I., Ginish, N., Anis, E., Mendelson, E., Mor, O., Zuckerman, N. S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101190 · Cited by 31
Antibody-mediated immunity to SARS-CoV-2 spike
Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 22
Blasioli, E., Mansouri, B., Tamvada, S. S., & Hassini, E. (2023) · Operations Research Forum · doi:10.1007/s43069-023-00194-8 · Cited by 31
Neutralizing antibody: a savior in the Covid-19 disease
Gupta, S. L., & Jaiswal, R. K. (2022) · Molecular Biology Reports · doi:10.1007/s11033-021-07020-6 · Cited by 28
Jodaylami, M. H., Djaïleb, A., Ricard, P., Lavallée, É., Cellier-Goetghebeur, S., Parker, M.-F., Coutu, J., Stuible, M., Gervais, C., Durocher, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00844-z · Cited by 28
Imai, N., Hogan, A. B., Williams, L. R., Cori, A., Mangal, T. D., Winskill, P., Whittles, L. K., Watson, O. J., Knock, E., Baguelin, M., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16992.1 · Cited by 21
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-400230/v1 · Cited by 27
A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants
Pishesha, N., Harmand, T. J., Rothlauf, P. W., Praest, P., Alexander, R., van den Doel, R., Liebeskind, M. J., Vakaki, M. A., McCaul, N., Wijne, C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116147118 · Cited by 35
Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
Zhang, Y., Ndzouboukou, J. B., Gan, M., Lin, X., & Fan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771242 · Cited by 21
Multi-Epitope Vaccine Design Using an Immunoinformatic Approach for SARS-CoV-2
Feng, Y., Jiang, H., Qiu, M., Liu, L., Zou, S., Li, Y., Guo, Q., Han, N., Sun, Y., Wang, K., et al. (2021) · Pathogens · doi:10.3390/pathogens10060737 · Cited by 28
Mass spectrometric identification of immunogenic SARS-CoV-2 epitopes and cognate TCRs
Pan, K., Chiu, Y., Huang, E. L., Chen, M. M., Wang, J., Lai, I. P., Singh, S., Shaw, R., MacCoss, M. J., & Yee, C. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111815118 · Cited by 32
Chen, C., Lai, C.-C., Luh, D., Chuang, S., Yang, K., Yeh, Y., Yen, A. M., Chang, K., Chang, R., & Chen, S. L. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.05.022 · Cited by 24
Qu, P., Faraone, J. N., Evans, J. P., Zou, X., Zheng, Y.-M., Carlin, C., Bednash, J. S., Lozanski, G., Mallampalli, R. K., Saif, L. J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.16.492158 · Cited by 21
Li, C., Yu, Y., Wan, Z., Chiu, M. C., Huang, J., Zhang, S., Zhu, X., Lan, Q., Deng, Y., Zhou, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55076-2 · Cited by 26
Joshi, G., Borah, P., Thakur, S., Sharma, P., Mayank, M., & Ramarao, P. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1995283 · Cited by 28
Multi-Organ Histopathological Changes in a Mouse Hepatitis Virus Model of COVID-19
Paidas, M. J., Mohamed, A. S., Norenberg, M. D., Ali, S., Barry, A. F., Colon, C., Kenyon, N. S., & Jayakumar, A. R. (2021) · Viruses · doi:10.3390/v13091703 · Cited by 26
Acosta, N., Bautista, M. A., Waddell, B. J. M., Du, K., McCalder, J., Pradhan, P., Sedaghat, N., Papparis, C., Beaudet, A. B., Chen, J., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28442 · Cited by 33
Therapeutics to Tackle Omicron Outbreak
Chavda, V. P., Ghali, E. N. H. K., Yallapu, M. M., & Apostolopoulos, V. (2022) · Immunotherapy · doi:10.2217/imt-2022-0064 · Cited by 31
Jawalagatti, V., Kirthika, P., Hewawaduge, C., Yang, M., Park, J.-Y., Oh, B., & Lee, J. H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.042 · Cited by 24
The Emergence of SARS-CoV-2 within the Dog Population in Croatia: Host Factors and Clinical Outcome
Stevanović, V., Tabain, I., Vilibić‐Čavlek, T., Maurić, M., Benvin, I., Hruškar, Ž., Kovač, S., Šmit, I., Miletić, G., Hađina, S., et al. (2021) · Viruses · doi:10.3390/v13081430 · Cited by 26
Park, S. W., Bolker, B. M., Funk, S., Metcalf, C. J. E., Weitz, J. S., Grenfell, B. T., & Dushoff, J. G. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0173 · Cited by 44
Xu, K., An, Y., Li, Q., Huang, W., Han, Y., Zheng, T., Fang, F., Liu, H., Liu, C., Gao, P., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1959270 · Cited by 25
Denaturation of the SARS-CoV-2 spike protein under non-thermal microwave radiation
Afaghi, P., Lapolla, M. A., & Ghandi, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-02753-7 · Cited by 23
Gupta, N., Kaur, H., Yadav, P., Mukhopadhyay, L., Sahay, R., Kumar, A., Nyayanit, D. A., Shete, A., Patil, S. V., Majumdar, T., et al. (2021) · medRxiv · doi:10.1101/2021.07.13.21260273 · Cited by 24
Kayode, A. J., Banji-Onisile, F. O., Olaniran, A. O., & Okoh, A. I. (2021) · Pathogens · doi:10.3390/pathogens10091108 · Cited by 23
Gage, A., Brunson, K., Morris, K., Wallen, S. L., Dhau, J. S., Gohel, H., & Kaushik, A. K. (2021) · Frontiers in Nanotechnology · doi:10.3389/fnano.2021.700888 · Cited by 26
Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19
Lu, R., Ko, S.-H., Wy, C., Chang, Y., Lin, H.-T., & Wu, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212412 · Cited by 25
Tan, Y., Zhang, W., Zhu, Z., Qiao, N., Ling, Y., Guo, M., Tong, Y., Fang, H., Xu, X., Lü, G., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00274-1 · Cited by 29
Competition of SARS-CoV-2 variants on the pandemic transmission dynamics
Chen, J., Gu, C., Ruan, Z., & Tang, M. (2023) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2023.113193 · Cited by 19
Anwar, M. Z., Lodhi, M. S., Khan, M. T., Khan, M. I., & Sharif, S. (2022) · Genes · doi:10.3390/genes13030552 · Cited by 21
Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out
Mumtaz, G. R., El‐Jardali, F., Jabbour, M., Harb, A., Abu-Raddad, L. J., & Makhoul, M. (2021) · Vaccines · doi:10.3390/vaccines9070697 · Cited by 23
Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development
He, X., He, C., Hong, W., Yang, H. J., & Wei, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21941 · Cited by 25
Boudewijns, R., Pérez, P., Lázaro-Frías, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845969 · Cited by 23
Beeraka, N. M., Sukocheva, O. A., Lukina, E., Liu, J., & Fan, R. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2346 · Cited by 23
Sagara, I., Woodford, J., Koné, M., Assadou, M. H., Katilé, A., Attaher, O., Zéguimé, A., Doucoure, M., Higbee, E., Lane, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab589 · Cited by 41
Agurto-Arteaga, A., Poma-Acevedo, A., Ríos-Matos, D., Choque-Guevara, R., Montesinos, R., Montalván-Ávalos, Á., Isasi-Rivas, G., Cauna-Orocollo, Y., Mendoza, M. D. G. C., Pérez-Martínez, N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.881604 · Cited by 23
Salvagno, G. L., Henry, B. M., di, P., Pighi, L., NITTO, S. D., Bragantini, D., Gianfilippi, G. L., & Lippi, G. (2021) · Journal of Medical Biochemistry · doi:10.5937/jomb0-32373 · Cited by 21
Tissue immunity to SARS‐CoV‐2: Role in protection and immunopathology*
Rybkina, K., Davis‐Porada, J., & Färber, D. L. (2022) · Immunological Reviews · doi:10.1111/imr.13112 · Cited by 19
Hamdy, R., Fayed, B., Mostafa, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169057 · Cited by 22
Recent advances in enzyme-free and enzyme-mediated single-nucleotide variation assay in vitro
Xiong, E., Liu, P., Deng, R., Zhang, K., Yang, R., & Li, J. (2024) · National Science Review · doi:10.1093/nsr/nwae118 · Cited by 27
A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
Shan, S., Mok, C. K., Zhang, S., Lan, J., Li, J., Yang, Z., Wang, R., Cheng, L., Fang, M., Aw, Z. Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.766821 · Cited by 21
Clinical challenges of SARS‑CoV‑2 variants (Review)
Cojocaru, C., Cojocaru, E., Turcanu, A., & Zaharia, D. C. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11343 · Cited by 29
The mechanisms of immune response and evasion by the main SARS-CoV-2 variants
Chen, Q., Zhang, J., Wang, P., & Zhang, Z. (2022) · iScience · doi:10.1016/j.isci.2022.105044 · Cited by 27
Caza, M., Hogan, C. A., Jassem, A. N., Prystajecky, N., Hadzic, A., & Wilmer, A. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104996 · Cited by 17
Noori, M., Nejadghaderi, S. A., & Rezaei, N. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.199 · Cited by 22
COVID-19: Epidemiologie und Mutationen
Hemmer, C. J., Löbermann, M., & Reisinger, E. C. (2021) · Der Radiologe · doi:10.1007/s00117-021-00909-0 · Cited by 33
Sugiyama, M. G., Cui, H., Redka, D. S., Karimzadeh, M., Rujas, E., Maan, H., Hayat, S., Cheung, K., Misra, R., McPhee, J. B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02432-7 · Cited by 24
Paul, G. K., Mahmud, S., Aldahish, A. A., Afroze, M., Biswas, S., Gupta, S. B. R., Razu, M. H., Zaman, S., Uddin, M. S., Nahari, M. H., et al. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103600 · Cited by 25
Li, F., Ghiabi, P., Hajian, T., Klíma, M., Li, A. S. M., Yazdi, A. K., Chau, I., Loppnau, P., Kutera, M., Seitova, A., et al. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130319 · Cited by 35
Machado, R. R. G., Glaser, T., Araújo, D. B., Petiz, L. L., Oliveira, D. B. L., Durigon, G. S., Leal, A. L., Pinho, J. R. R., Ferreira, L. C. S., Ulrich, H., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00080 · Cited by 44
Metadata
- Authors
- Abdool Karim, S. S., & de Oliveira, T.
- Affiliations
- Centre for the AIDS Program of Research in South Africa, Durban, South Africa
- KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Durban, South Africa
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-13
- Volume
- 384
- Issue
- 19
- Pages
- 1866-1868
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8008749
- OpenAlex
- W3138447431
- Cited by
- 699
- References
- 0
- Citations by year
- 2026: 12 · 2025: 21 · 2024: 35 · 2023: 94 · 2022: 260 · 2021: 274
- FWCI
- 52.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- SARS-CoV-2 variants, Alpha variant, Beta variant, P.1, Omicron variant, clinical implications, public health implications, COVID-19 pandemic
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, United Kingdom, Humans, Mutation, South Africa, Treatment Outcome, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
